NCT05997485View on ClinicalTrials.gov

A Study to Learn About the Patients With COVID-19 Prescribed Paxlovid in Morocco

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

March 30, 2024

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions
COVID-19 Drug Treatment
Interventions
DRUG

Nirmatrelvir/Ritonavir

Patients administered oral Paxlovid as prescribed according to national Morocco treatment guidelines for Covid.

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05997485 - A Study to Learn About the Patients With COVID-19 Prescribed Paxlovid in Morocco | Biotech Hunter | Biotech Hunter